Company / Return on Equity (ROE)
Editas Medicine, Inc. Return on Equity (ROE) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-176.6%
FY2025
5-year range
-176.6% / -29.5%
FY2021-FY2025
Trend
-179.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Editas Medicine, Inc. reports negative total equity of -176.6% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-176.6% in FY2025 with a 5-year CAGR of -130.0%.
Declined from -34.8% to -176.6% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -147.1pp
- 5-Year Change
- -130.0pp
- 10-Year Change
- -
Key checks
Key Insights
- Editas Medicine, Inc.'s return on equity (roe) has declined for 3 consecutive years.
- In FY2025, return on equity (roe) decreased 179.6% year-over-year.
- Peak return on equity (roe) was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -176.6% | -179.6% |
| FY2024 | -63.1% | -81.6% |
| FY2023 | -34.8% | -18.0% |
| FY2022 | -29.5% | +42.2% |
| FY2021 | -51.0% | -9.5% |
| FY2020 | -46.6% | +19.5% |
| FY2019 | -57.8% | +19.9% |
| FY2018 | -72.2% | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026